0.84
+0.0091(+1.10%)
Currency In USD
| Previous Close | 0.83 |
| Open | 0.84 |
| Day High | 0.86 |
| Day Low | 0.84 |
| 52-Week High | 6.89 |
| 52-Week Low | 0.64 |
| Volume | 116,339 |
| Average Volume | 1.22M |
| Market Cap | 8.45M |
| PE | 0.65 |
| EPS | 1.3 |
| Moving Average 50 Days | 3.17 |
| Moving Average 200 Days | 2.66 |
| Change | 0.01 |
If you invested $1000 in iBio, Inc. (IBIO) 10 years ago, it would be worth $0.2 as of May 09, 2025 at a share price of $0.839. Whereas If you bought $1000 worth of iBio, Inc. (IBIO) shares 5 years ago, it would be worth $1.5 as of May 09, 2025 at a share price of $0.839.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
GlobeNewswire Inc.
May 05, 2025 12:00 PM GMT
Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in
iBio Reports Fiscal Third Quarter 2025 Financial Results
GlobeNewswire Inc.
May 02, 2025 12:00 PM GMT
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. “During the third quarter we were able to broaden ou
iBio Raises $6.2 Million Through Warrant Inducement Transaction
GlobeNewswire Inc.
Apr 29, 2025 5:43 PM GMT
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors